Journal
TRENDS IN MOLECULAR MEDICINE
Volume 17, Issue 2, Pages 108-116Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2010.10.008
Keywords
-
Funding
- Bill and Melinda Gates Foundation
- Center for HIV/AIDS Vaccine Immunology from the National Institutes of Health, National Institute of Allergy and Infectious Disease, Division of AIDS [AI0678501]
Ask authors/readers for more resources
The B cell arm of the immune response becomes activated soon after HIV-1 transmission, yet the initial antibody response does not control HIV-1 replication, and it takes months for neutralizing antibodies to develop against the autologous virus. Antibodies that can be broadly protective are made only in a minority of subjects and take years to develop too the earliest stages of HIV-1 infection, new techniques to probe the human B cell repertoire, the modest degree of efficacy in a vaccine trial and new studies of human monoclonal antibodies that represent the types of immune responses an HIV-1 vaccine should induce are collectively illuminating paths that a successful HIV-1 vaccine might take.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available